Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

@article{Munster2009ClinicalAB,
  title={Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC},
  author={Pamela N. Munster and Douglas C. Marchion and Elona Biçaku and Mira Lacevic and Jongphil Kim and Barbara Ann Centeno and Adil I. Daud and Anthony M Neuger and Susan E. Minton and Daniel C. Sullivan},
  journal={Clinical Cancer Research},
  year={2009},
  volume={15},
  pages={2488 - 2496}
}
Purpose: The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies. Experimental Design: A phase I dose escalation of valproic acid given on days 1 to 3 followed by epirubicin (day 3) was followed by a dose expansion of valproic acid combined with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC100). Pharmacodynamic and pharmacokinetic studies entailed valproic acid and epirubicin plasma… 

Figures and Tables from this paper

Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer
TLDR
Valproic acid can be administered to dogs at doses up to 240 mg/kg/day prior to a standard dose of doxorubicin, and the pharmacokinetic/pharmacodynamic tools necessary for future studies of novel HDACi in the clinical setting of canine cancer are developed.
Cancer esearch cer Therapy : Preclinical se I Pharmacokinetic and Pharmacodynamic Evaluation ombined Valproic Acid / Doxorubicin Treatment in Dogs R Spontaneous Cancer
TLDR
A positive correlation was detected between valproic acid dose and histone hyperacetylaperipheral blood mononuclear cells and the pharmacokinetic/pharmacodynamic tools necessary for future studies of novel HDACi in the clinical setting of canine cancer.
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
TLDR
Findings suggest that vorinostat can be combined with weekly doxorubicin in this schedule at a dose of 800 mg day−1, and the HDAC2 expression may be a marker predictive of HDAC inhibition.
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
  • S. Thomas, R. Aggarwal, P. Munster
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
TLDR
Panobinostat and epirubicin treatment is well tolerated and may reverse anthracycline resistance and warrant investigation as predictive biomarkers.
Spontaneous Cancer
TLDR
A positive correlation was detected between valproic acid dose and histone hyperacetylaperipheral blood mononuclear cells and the pharmacokinetic/pharmacodynamic tools necessary for future studies of novel HDACi in the clinical setting of canine cancer.
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
TLDR
Abexinostat is well tolerated in combination with pazopanib, allowing prolonged exposure and promising durable responses in pazobanib- and other VEGF inhibitor-refractory tumors, which supports epigenetically mediated reversal of treatment resistance.
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
TLDR
Correlative studies suggest that HDAC2 expression is a predictive marker and histone hyperacetylation is a useful pharmacodynamic marker for the efficacy of this combination of vorinostat and tamoxifen, and exhibits encouraging activity in reversing hormone resistance.
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
TLDR
This study could provide a less toxic and more effective first-line chemotherapy regimen in patients with recurrent/metastatic squamous cell carcinoma of the head and neck by demonstrating the feasibility and efficacy of cisplatin/cetuximab plus valproic acid.
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
TLDR
Although preliminary, this study represents the first randomized clinical trial to demonstrate a significant advantage in progression-free survival for epigenetic therapy over one of the current standard combination chemotherapy in cervical cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 68 REFERENCES
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
  • P. Münster, D. Marchion, A. Daud
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
The maximum-tolerated dose and recommended phase II dose was VPA 140 mg/kg/d for 48 hours followed by epirubicin 100 mg/m2 and noteworthy antitumor activity was observed in heavily pretreated patients and historically anthracycline-resistant tumors.
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
TLDR
Neurocognitive impairment dominated the toxicity profile, with grade 3 or 4 neurological side effects occurring in 8 out of 26 patients, and dose-limiting toxicity (DLT) was the main DLT of infusional VPA.
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
  • O. O’Connor, M. Heaney, W. Kelly
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Results suggest that SAHA has activity in hematologic malignancies including HD and select subtypes of non-Hodgkin's lymphoma.
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
TLDR
Both schedules of vorinostat were tolerated well in combination with carboplatin and paclitaxel, and encouraging anticancer activity was noted in patients with previously untreated non–small cell lung cancer.
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
TLDR
Exposure of tumor-bearing mice to valproic acid potentiated the antitumor effects of topoisomerase II inhibitors without enhancing toxicity, and ex vivo comet assays may be useful as a predictive tool when tumor cells are limited and serial biopsies are difficult to obtain.
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
TLDR
Intravenous administration of LBH589 was well tolerated at doses <11.5 mg/m2 with consistent transient antileukemic and biological effects and significantly increased acetylation of histones H2B and H3 in CD34+ and CD19+ cells significantly increased on therapy as did apoptosis in CD14+ cells.
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
TLDR
The results show that MS-275 effectively inhibits HDAC in vivo in patients with advanced myeloid leukemias and should be further tested, preferably in Patients with less-advanced disease.
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
TLDR
MS-275 is well tolerated at doses up to 6 mg/m2 every other week or 4 mg/ m2 weekly for 3 weeks followed by 1 week of rest and results in biologically relevant plasma concentrations and antitumor activity and is recommended for further disease-focused studies.
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
TLDR
Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients.
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
  • V. Sandor, S. Bakke, S. Bates
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
The maximum tolerated dose (MTD) of depsipeptide given on a day-1 and -5 schedule every 21 days was defined and biological assays showed that the serum levels achieved could cause the characteristic cell cycle effects of this agent when serum was added to PC3 cells in culture, as well as increased histone acetylation in patient-derived peripheral blood mononuclear cells.
...
1
2
3
4
5
...